ArticleNature biotechnology2017
Payer coverage policies for multigene tests.
Article in Nature biotechnology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Urine as a source of biomarkers and biological knowledge in chronic kidney disease.Nature reviews. Nephrology · 2026Review
- State-level opportunities to advance biomarker testing in patients with advanced cancers and state-regulated plans.Future oncology (London, England) · 2025Article
- Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations.Journal of Alzheimer's disease : JAD · 2025Review
- Claim Denials for Cancer-Related Next-Generation Sequencing in Medicare.JAMA network open · 2025Article
- Article
- Private Payer and Medicare Coverage Policies for Use of Circulating Tumor DNA Tests in Cancer Diagnostics and Treatment.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Article
- Reimbursement of pharmacogenetic tests at a tertiary academic medical center in the United States.Frontiers in pharmacology · 2023Article
- Genetic counselors' experience with reimbursement and patient out-of-pocket cost for multi-cancer gene panel testing for hereditary cancer syndromes.Journal of genetic counseling · 2022Article
- Cost-effectiveness of precision molecular diagnostic tests for stage II colorectal cancer.Annals of translational medicine · 2022Article
- Toward a More Just System of Care in Molecular Pathology.The Milbank quarterly · 2022Article
- Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018.Hereditary cancer in clinical practice · 2022Article
- Ethical Considerations for Equitable Access to Genomic Sequencing for Critically Ill Neonates in the United States.International journal of neonatal screening · 2022Article
- US private payers' perspectives on insurance coverage for genome sequencing versus exome sequencing: A study by the Clinical Sequencing Evidence-Generating Research Consortium (CSER).Genetics in medicine : official journal of the American College of Medical Genetics · 2022Article
- The diagnostic trajectory of infants and children with clinical features of genetic disease.NPJ genomic medicine · 2021Article
- Outcomes of prior authorization requests for genetic testing in outpatient pediatric genetics clinics.Genetics in medicine : official journal of the American College of Medical Genetics · 2021Article
- Private Payer and Medicare Coverage for Circulating Tumor DNA Testing: A Historical Analysis of Coverage Policies From 2015 to 2019.Journal of the National Comprehensive Cancer Network : JNCCN · 2020Article
- Pharmacogenetics in Practice: Estimating the Clinical Actionability of Pharmacogenetic Testing in Perioperative and Ambulatory Settings.Clinical and translational science · 2020Article
- Insights From a Temporal Assessment of Increases in US Private Payer Coverage of Tumor Sequencing From 2015 to 2019.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020Article
- Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing.Journal of genetic counseling · 2019Article
- Insurance coverage does not predict outcomes of genetic testing: The search for meaning in payer decisions for germline cancer tests.Journal of genetic counseling · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.